SUPRANE Drug Patent Profile

When do Suprane patents expire, and when can generic versions of Suprane launch?

Suprane is a drug marketed by Baxter Hlthcare and is included in one NDA.

The generic ingredient in SUPRANE is desflurane. There are three drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the desflurane profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Suprane

A generic version of SUPRANE was approved as desflurane by SHANGHAI HENGRUI on February 26^th, 2018.

Summary for SUPRANE

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	55
Clinical Trials:	35
Patent Applications:	1,352
Drug Prices:	Drug price information for SUPRANE
What excipients (inactive ingredients) are in SUPRANE?	SUPRANE excipients list
DailyMed Link:	SUPRANE at DailyMed

See drug prices for SUPRANE

Recent Clinical Trials for SUPRANE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Cancer Institute, Egypt	N/A
Sefako Makgatho Health Sciences University	N/A
Ayse Cigdem Tutuncu	N/A

See all SUPRANE clinical trials

Pharmacology for SUPRANE

Drug Class	General Anesthetic
Physiological Effect	General Anesthesia

Paragraph IV (Patent) Challenges for SUPRANE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SUPRANE	Inhalation	desflurane	99.9%	020118	1	2008-09-11

US Patents and Regulatory Information for SUPRANE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Baxter Hlthcare	SUPRANE	desflurane	LIQUID;INHALATION	020118-001	Sep 18, 1992	AN	RX	Yes	Yes

Expired US Patents for SUPRANE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Baxter Hlthcare	SUPRANE	desflurane	LIQUID;INHALATION	020118-001	Sep 18, 1992	4,762,856*PED
Baxter Hlthcare	SUPRANE	desflurane	LIQUID;INHALATION	020118-001	Sep 18, 1992	5,617,906*PED

International Patents for SUPRANE

See the table below for patents covering SUPRANE around the world.

Country	Patent Number	Title	Estimated Expiration
Norway	305058
Australia	658170
Norway	880434
World Intellectual Property Organization (WIPO)	9212752

Supplementary Protection Certificates for SUPRANE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0285237	94C0006	France		PRODUCT NAME: DIDANOSINE; NAT. REG.: 203 IS 225 F 3 19930331; FIRST REG.: FR 557 386-4 19920505
0285237	95C0008	Belgium		PRODUCT NAME: ESTRADIOL, HEMIHYDRATE; NAT. REGISTRATION NO/DATE: NL 19489 19941107; FIRST REGISTRATION: FR - NL 19489 19941107

SUPRANE Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Suprane (Desflurane)

Introduction to Suprane (Desflurane)

Suprane, known chemically as desflurane, is a highly potent inhalational anesthetic used in surgical procedures. It is part of the broader inhalation anesthesia market, which is experiencing significant growth driven by various factors.

Market Size and Growth

The global inhalation anesthesia market, which includes Suprane, is projected to grow substantially over the coming years. As of 2024, the market size was estimated at USD 2.02 billion and is expected to reach USD 3.61 billion by 2034, growing at a CAGR of 5.97%[1].

Segment Performance

Within the inhalation anesthesia market, the segment that includes desflurane (Suprane) is an important component. Although sevoflurane dominates the market with the largest share, desflurane remains a critical player due to its unique properties and applications. Desflurane is known for its rapid onset and recovery times, making it suitable for a wide range of surgical procedures[4].

Competitive Landscape

Baxter International is a major player in the inhalation anesthesia market, including the segment for desflurane. Baxter is the only company that offers all three commonly used inhaled anesthetics: isoflurane, sevoflurane, and desflurane (Suprane). This market position is strengthened by high barriers to entry and strong switching costs, primarily due to the complexity of manufacturing these anesthetics and the proprietary vaporizer hardware installed by manufacturers[2].

Barriers to Entry and Switching Costs

The complexity of manufacturing inhaled anesthetics, such as desflurane, acts as a significant barrier to entry for new competitors. Additionally, the proprietary vaporizer hardware required for these anesthetics further increases switching costs for healthcare providers. These factors contribute to Baxter's dominant market share, estimated to be over 50% in the inhaled anesthetics segment[2].

Generic Competition

While desflurane (Suprane) has faced the expiration of its patents, generic competition has been slower to materialize due to the technical challenges involved in manufacturing these drugs. Isoflurane and sevoflurane, other anesthetics offered by Baxter, already face generic competition from companies like AbbVie and Piramal. However, the unique manufacturing requirements for desflurane have helped maintain its market position despite the loss of patent protection[2].

Market Drivers

Several factors drive the demand for desflurane and the broader inhalation anesthesia market:

• Increasing Surgical Procedures: The global rise in surgical procedures, particularly in outpatient and same-day discharge contexts, increases the demand for anesthetics that promote faster recovery times. Desflurane's rapid onset and recovery characteristics make it an ideal choice for these settings[4].
• Patient Safety and Efficacy: The market is shifting toward agents that emphasize both effective sedation and patient safety. Desflurane's favorable pharmacokinetic properties, such as minimal airway irritation and stable hemodynamics, contribute to its popularity[4].

Financial Trajectory for Baxter

Baxter International, the primary manufacturer of desflurane, is expected to see significant financial growth in the coming years. Despite current headwinds such as generic competition and regulatory issues, Baxter's long-term outlook is positive.

• Revenue Growth: Baxter's revenue growth potential is near 6%, driven largely by higher growth opportunities in segments such as renal, nutrition, and biosurgery. The anesthetics segment, including desflurane, is expected to contribute to this growth[2].
• Margin Expansion: Baxter is anticipated to achieve nearly 500 basis points of margin expansion over the next five years, driven by cost control measures, optimization of manufacturing and distribution operations, and a focus on higher-margin segments[2].
• Free Cash Flow: Improved profitability and lower capital spending are expected to push free cash flow near $1.3 billion by 2019, according to estimates. This translates into returns on capital near 12% and a cost of equity at 9%[2].

Regional Market Dynamics

The inhalation anesthesia market, including desflurane, is geographically diverse with significant presence in:

• North America: This region is the largest market for inhalation anesthetics, driven by advanced healthcare infrastructure and high demand for surgical procedures[1].
• Europe and Asia Pacific: These regions are also experiencing growth, driven by increasing healthcare spending and the rise in surgical procedures[1].

Challenges and Opportunities

While the market for desflurane is poised for growth, there are several challenges and opportunities to consider:

• Regulatory Issues: Baxter has faced regulatory challenges, including warning letters from the FDA. However, these issues are not seen as major threats to the business at this time[2].
• Emerging Markets: Baxter's exposure to emerging markets, which account for about 25% of its sales, presents significant growth opportunities. The company's international presence supports its long-term growth outlook[2].

Key Takeaways

• The inhalation anesthesia market, including desflurane, is expected to grow significantly, reaching USD 3.61 billion by 2034.
• Baxter International dominates the market with a strong position in inhaled anesthetics, including desflurane.
• High barriers to entry and switching costs protect Baxter's market share.
• Increasing surgical procedures and a focus on patient safety drive demand for desflurane.
• Baxter's financial trajectory includes revenue growth, margin expansion, and improved free cash flow.

FAQs

Q: What is the projected market size for the inhalation anesthesia market by 2034? A: The inhalation anesthesia market is projected to reach USD 3.61 billion by 2034[1].

Q: Who is the dominant player in the inhaled anesthetics market? A: Baxter International is the dominant player, offering all three commonly used inhaled anesthetics: isoflurane, sevoflurane, and desflurane (Suprane)[2].

Q: What are the main drivers for the demand of desflurane? A: The main drivers include the increasing number of surgical procedures, particularly in outpatient settings, and the emphasis on patient safety and efficacy[4].

Q: How does generic competition affect the market for desflurane? A: Despite patent expiration, generic competition for desflurane has been slow due to the complexity of manufacturing and proprietary vaporizer hardware[2].

Q: What is the expected revenue growth rate for Baxter International in the coming years? A: Baxter's revenue growth potential is near 6%, driven by higher growth opportunities in segments such as renal, nutrition, and biosurgery[2].

Sources

1. Precedence Research: Inhalation Anesthesia Market Size To Hit USD 3.61 Bn By 2034[1].
2. Morningstar: Baxter's Headwinds Mostly Temporary[2].
3. Market Research Intellect: Global Sevoflurane and Desflurane Anaesthetics Market Size[3].
4. Grand View Research: Inhalation Anesthesia Market Size And Share Report, 2030[4].